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Abstract
Dual diagnosis (DD) is the coexistence of severe mental illness (SMI) and substance
use  disorder  (SUD).  The  increase  of  DD  observed  in  recent  years  has  important
implications for mental health services organization. The aim of this study is to assess
the prevalence and features of DD over a decade, comparing the periods 2003–2004
and 2013–2014. We performed a retrospective study retrieving sociodemographic and
clinical  data  from  the  medical  records  of  patients  at  their  first  admission  to  the
Psychiatric  Ward of  University Hospital  “Maggiore della  Carità” in Novara,  Italy.
Patients  with  SMI  and comorbid  SUD (SMI-SUD) and patients  with  SMI  without
comorbidity (SMI) were compared in the two periods, 2003–2004 versus 2013–2014.
SMI-SUD  patients  in  both  2-year  periods  were  more  likely  to  be  male,  younger,
unemployed, living with parents (or alone, for the 2013–2014 period) rather than with
a family of their own, and single (or divorced, in 2003–2004). The 2003–2004 patients
were  more  frequently  diagnosed  with  a  personality  disorder,  whereas  the  2013–
2014  patients  had  mixed  diagnoses.  We  have  found  differences  in  the  possible
predictors of substance abuse in the two periods as well: in both periods, male gender
was associated with an increased risk of DD, whereas age >61 years was associated
with decreased risk.  Only in  the  first  period (2003–2004)  was having a  university
degree associated with a decreased risk of DD, whereas the diagnosis of a personal‐
ity  disorder  was associated with an increased risk of  DD;  on the contrary,  in  the
second period (2013–2014), living in a protective environment was associated with a
decreased  risk  of  DD.  The  identification  of  changes  in  the  prevalence  of  first
admission DD patients and their clinical and sociodemographic features may help to
highlight an evolving pattern of substance use and to identify possible risk factors
that may be the target of prevention and treatment approaches.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
1.1. Addiction
The pathway that leads to addiction is characterized by specific steps: the initiation of sub‐
stance use, the established use, and, finally, the development of addiction. Several factors are
involved in this process, including genetic and environmental ones. The availability of the
substance may play a role in each stage in the development of addiction, whereas the accessi‐
bility of a substance seems relatively more important in the initiation of substance use [1].
Evidence from family, adoption, and twin studies converges on the relevance of genetic factors
in the development of addiction according to a complex model of inheritance and clinical and
genetic heterogeneity [2–10]. The role of genetic, sociocultural, biological, and other factors,
including drug availability, peer influence, social support, and type and psychoactive proper‐
ties of the drug, varies across the lifespan and in different stages of the addiction process. Briefly,
it seems that environmental factors (such as peer influences and family environment) have a
stronger effect on exposure and initial pattern of use, whereas genetic factors play a major role
in the transition from regular use to the development of addiction [11,12]. Moreover, it should
not be overlooked that genetic factors underlying addiction may overlap to various degrees
with those underlying other psychiatric disorders. For instance, studies focusing on the role of
the COMT gene polymorphism in the genetic predisposition to mental disorders [including
severe mental illness (SMI), such as schizophrenia, bipolar disorder, obsessive-compulsive
disorder, anorexia nervosa, and attention-deficit hyperactivity disorder] have found that the
same polymorphism may be involved in the pathogenesis of addiction and substance use
disorder (SUD). Probably COMT increases susceptibility to mental disorders in general, whereas
other genetic or environmental factors may influence the development of specific disorders,
including SUD [13].
1.2. Dual diagnosis (DD)
The World Health Organization defines DD as the co-occurrence, in the same person, of a
severe mental health condition (SMI) with a drug abuse or dependence disorder (SUD).
In 1993, First and Gladis [14] proposed to classify DD patients as follows: (1) main psychiat‐
ric disorder and secondary drug dependence, (2) main SUD and secondary psychiatric
disorder, and (3) main psychiatric disorder and drug dependence. Discriminating among these
three options may be particularly challenging in clinical settings, where it can be hard to
understand whether it is the SMI that induced drug consumption or the drug consumption
that induced or worsened the SMI.
Recent Advances in Drug Addiction Research and Clinical Applications170
Consistent with the first class proposed by First and Gladis (psychiatric disorder first and
subsequent drug dependence), the study of the psychological attitudes in addiction disor‐
ders has lead to the self-medication hypothesis (SMH) proposed by Khantzian [15]. The SMH
primarily derives from clinical observations and posits substance dependence as a compen‐
satory means to modulate emotions and aimed at self-soothing in response to distressing
psychological states. According to this hypothesis, drugs would become addicting because of
their power to alleviate, counteract, or modulate psychological suffering; there would also be
a considerable degree of specificity in a person’s choice of drugs because of unique psycho‐
logical and physiological effects [15]. Hence, emotional states and distress, as well as expect‐
ancy of positive affective modifications, would be associated with substance use or relapse in
people with SUD [16]. The SMH has received a variable empirical support, particularly as far
as drug specificity is concerned [17]. The choice of type of drug according to the SMH is
sometimes counterintuitive. For instance, while DD bipolar patients seem to use substances to
maintain a euphoric state or soothe a depressive suffering, depressed patients, who might be
expected to choose stimulants as well, often turn to depressants such as alcohol. Schizophren‐
ic patients are often strongly nicotine addicted, and their heavy smoking may be an attempt
to alleviate cognitive deficits and to reduce extrapyramidal side effects induced by antipsy‐
chotic medication, through the effect of nicotine on dopaminergic activity [18]. Briefly, the
choice of a particular type of substance could depend on the symptoms that patients wish to
relieve, as well as on substance availability, and on patients’ basic personality traits [19].
Moreover, clinical experience in the last years has highlighted clear and ongoing changes in
the choice of type of drug [from heroin and lysergic acid diethylamide (LSD) to the current so-
called “smart drugs”, vegetable or synthetic origin compounds with psychoactive effects that
are not yet considered illegal]. For instance, changes in the prevalence of commonly used
substances in people with DD have been discussed in two studies that estimated the preva‐
lence of SUD in patients with SMI in Philadelphia [20,21]. These studies found a shift from
cannabis being the most commonly used drug to cocaine and associated changes in demo‐
graphic correlates. Although these data date back to more than 20 years ago, they highlight
the changing pattern of SUD [22,23].
Consistent with these results, in Italy, in the last two decades, significant changes in the main
drug used by patients attending addiction services have been noticed. Although the use of
alcohol has remained relatively stable, there has been a significant decrease in the use of heroin
and an opposite tendency regarding the use of cocaine; moreover, the use of “smart drugs”
and polyabuse (i.e., the abuse of several substances simultaneously) has increased in an
alarming way. The reasons underlying the use of new drugs may be different from those
guiding the first heroin addicts. For instance, ecstasy has been generally chosen by adoles‐
cents and young adults for its entactogenic properties (the stimulation and enhancement of
feelings of empathy, love, and presumed emotional closeness to others) [24,25].
As already suggested, personality may play a relevant role in the choice of the drug and
expectations concerning the desired effect of the drug itself. The motivation leading to drug
abuse may span from alleviating boredom and active search for pleasure, improvement of
attention and performance, to reducing tension and decreasing mental illness symptoms.
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Hence, personality traits should be assessed to improve the understanding of the complex
relation between patients, drugs, and environment [26].
According to Cloninger’s model [27,28], personality consists of temperament and character
traits. Temperament is defined as a biological disposition reflected by relatively stable features
related to mood, attitudes towards the environment, and reactivity to external and internal
stimuli, including variability and intensity in emotional dispositions [29,30], whereas charac‐
ter is based on mechanisms that are developed through life experience. Although only a few
studies have investigated personality dimensions in DD patients with the model developed
by Cloninger, most of these found an association with high scores on the temperamental
dimension of “novelty seeking” [31,32] as well as with high scores on “harm avoidance” [31].
According to Cloninger’s descriptions of these temperament dimensions, we may expect
patients with high scores on “novelty seeking” using drugs to search pleasure and to escape
boredom and patients with high scores on “harm avoidance” using substances to achieve relief
from tension and unpleasant or painful emotional states [33].
1.3. Epidemiology and clinical features of DD patients
Comorbidity between drug and/or alcohol dependence and a SMI is highly prevalent, and
clinicians should be aware that patients asking for a psychiatric advice are likely to conceal
their problems related to use and/or abuse of substances, unless specifically asked about
them [34,35], possibly leading to an underestimation of DD. Recent studies report that the
prevalence of DD in patients attending mental health service and substance misuse services
ranges between 55% and 85% [36,37], and an association between SUD and mood and anxiety
disorders has been supported by epidemiological and clinical studies [38–41]. In 2014, in the
United States, among adults with a past year SUD, 39.1% had a comorbid psychiatric disor‐
der, whereas, among adults without a past year SUD, only 16.2% had a SMI [42]. Moreover,
epidemiological studies consistently describe a gender difference in DD patients as far as
diagnosis is concerned; overall, DD is more common in males, and male patients usually suffer
from psychotic and bipolar disorders, whereas depression and anxiety are more represented
in women who, on the contrary, represent a smaller percentage of DD samples [43,44].
Many longitudinal or cross-sectional studies tried to identify recurrent and significant
sociodemographic features and pattern/type of abuse typical of DD patients. The literature
suggests that DD patients, compared to those with SMI but no comorbidity with SUD, are
usually younger, males, with a lower level of education, often unemployed, still living with
parents rather than with a family of their own, and with an overall lower social functioning
[45–47]. DD is related to worst compliance to treatments, higher relapse rates and health
services usage, more functional disability, and cognitive as well as psychological, physical,
and social impairment [37,43,47,48]. Overall, DD patients show a poorer quality of life and
reduced life expectancy [49] compared with patients with SMI or patients with SUD with no
other comorbid psychiatric disorder.
The treatment of DD patients is particularly challenging because of the poor compliance and
significant deterioration in social functioning that often occurs in these patients. They are more
likely to suffer from comorbid medical conditions; as described above, they may experience
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more difficulties in family relationships and troubles maintaining a stable job and financial
situation; moreover, they may have legal problems related to the behavioral consequences of
substance use and/or to the illegal attempts to obtain the substance. Compared to schizophre‐
nia patients who do not use alcohol and drugs, patients with DD tend to have an earlier age
of onset, more frequent and sometimes longer periods of hospitalization, more severe
depressive and psychotic symptoms, more episodes of suicidal and violent behavior, more
legal and financial problems, and higher mortality risk [50–56]. Likewise, bipolar patients with
DD have 6.4-fold risk for violent crime compared with bipolar patients without comorbidity
[57,58]. Overall, because they are less likely to adhere to their medication regimen, patients
with DD also are at an increased risk of relapse and re-hospitalization [59,60]. However, even
in those who do adhere to their medication, commonly abused substances can trigger or
exacerbate psychiatric symptoms, eventually leading to relapse and need for inpatient
treatment.
Although, in the last years, several studies have been performed about early detection and
treatment of DD [59–64], there is a dearth of studies focused on the changes in the preva‐
lence of DD in psychiatric inpatients [65]. A study about comorbidity with SUD in psychiat‐
ric inpatients performed in Spain [66] found 24.9% of inpatients having a SUD as well as
another psychiatric disorder. Consistent with the literature about DD, a statistically signifi‐
cant predominance of men was found in the DD group together with younger age at the time
of their first psychiatric admission; the most common diagnoses in this group were schizo‐
phrenia or related psychoses, although patients with SMI only had mostly affective disor‐
ders. As described above for preferred substance of abuse, the most used was alcohol followed
by cannabis and cocaine.
Another interesting study assessing the trends in the incidence and demographic and clinical
correlates of DD among patients whose first psychiatric hospitalization occurred between 1996
and 2010 was performed in Israel by Ponizovsky et al. in 2015 [67]. Based on the literature and
their clinical experience, they hypothesized an increase of the proportion of DD among all first
psychiatric hospitalizations during the study period due to the increasing prevalence of
substance-related disorders in the general population, an increased vulnerability to DD on
behalf of specific population groups (e.g., new immigrants) [68–70], and, lastly, higher DD
rates in involuntarily hospitalized patients because they may be more likely to show epi‐
sodes of suicidal and violent behavior [52] compared to voluntarily admitted patients. Over
the study period, DD with drugs decreased from 1996 to 2010, whereas DD with alcohol and
DD with both drugs and alcohol increased. The changing pattern of DD over time was
supported as well as most findings concerning the sociodemographic features of DD pa‐
tients reported in the literature. The positive predictors of DD with alcohol were male gender,
previous suicide attempt, compulsory hospitalizations, and marital status. DD with alcohol
was found mainly in immigrants, whereas DD with drugs was more common in the native
population.
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1.4. Challenges and perspectives in research
Treatment of DD patients requires a thorough understanding of both mental illness and
addiction and the consequent integration of the traditional treatment approaches in both the
mental health and addiction treatment fields [71].
In the research field, a complicating issue for DD studies is that they may focus on different
populations: the general public, the population of subjects referring to psychiatric services,
and the population of people currently treated by addiction services [72]. This diversity
affecting the research field may be a concrete, challenging reality from a clinical standpoint.
In Italy, this is particularly important because the standard practice for patients with comor‐
bid psychiatric disorders and SUD is a parallel treatment. In our country, mental health and
addiction facilities have different institutional cultures, etiological concepts, administrative
arrangements, screening, and treatment approaches [73]. The problematic issues of such
treatment approach include possible flaws in communication, collaboration, and linkage,
which might significantly hinder or complicate comorbidity service delivery [74,75].
Even if it is clearly a changing and growing problem, the number of studies on DD preva‐
lence in patients admitted to psychiatric wards in general hospitals in Italy is still scant. A
recent study [76] has focused on differences in the length of stay in first-hospitalization
schizophrenic patients with and without comorbid SUD and found that the first showed poorer
symptom improvement and required longer stays than the latter. The flaws of communica‐
tion and linkage between psychiatric and addiction services emerged from the study by Preti
et al. [77], who reported that only approximately 30% of patients with SUD discharged from
acute psychiatric inpatient facilities were referred to drug addiction services. Other issues that
have been investigated in this field include SUD in emergency room settings [78], gender
differences in DD patients [65], and attempts to understand whether SUD follows or pre‐
dates the psychiatric diagnosis [79,80].
Considering these premises, the aim of our study was to describe the sociodemographic and
clinical features of DD patients at their first admission to the Psychiatric Ward of University
Hospital “Maggiore della Carità” in Novara, Italy. With more detail, we collected data about
all patients admitted for the first time during the 2-year periods 2003–2004 and 2013–2014 to
(1) assess the extent of comorbidity with drug abuse in a sample of patients at their first
admission to a psychiatric ward in a general hospital in Italy; (2) investigate whether there are
differences between inpatients with and without comorbid SUD, focusing on sociodemo‐
graphic, clinical, and other background variables in both periods; (3) investigate the possible
differences between patients with comorbid SUD in the two 2-year periods; and (4) identify
the possible predictors of comorbidity with SUD and their changes over a decade.
2. Methods
We performed a retrospective study reviewing the clinical charts of patients at their first
admission to the Psychiatric Ward of University Hospital “Maggiore della Carità” in Novara,
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Italy. We assessed two 2-year periods: 2003–2004 and 2013–2014. We excluded the records of
patients with a diagnosis at discharge of SUD with no comorbid psychiatric disorder. Because
our interest was to focus on DD, we collected data about patients with comorbid psychiatric
and SUD diagnosis (later on described as SMI-SUD) and about psychiatric patients without
comorbid SUD (SMI).
The following information was retrieved from the clinical charts: (1) sociodemographic data,
including age, sex, education, occupational status, living accommodation, marital status, and
legal problems and (2) clinical and psychopathological history, information concerning drug
use, history of self-harm (including suicidal and parasuicidal behaviors), and history of
aggressive behaviors and acting out.
Psychiatric diagnoses were made during the hospital stay by experienced psychiatrists with
the aid of the Structured Clinical Interview I [81] and II [82] for Axis I and Axis II disorders,
respectively. According to the International Classification of Diseases [83], diagnoses were the
following: schizophrenia and other psychoses, affective disorders, anxiety disorders, and
personality disorders; disturbance of conduct, mental retardation, eating disorders, acute
stress reaction, and adaptation reaction were grouped as “other diagnoses”.
Information about the use of psychotropic drugs was collected by the treating psychiatrist
during inpatient treatment, including age at first use and type of substance (alcohol, psychi‐
atric drugs, cannabis, heroin, and cocaine; methamphetamine, ketamine, phencyclidine, LSD,
butyl nitrite, amyl nitrite, and γ-hydroxybutyric acid were grouped together as “other drugs”).
As for diagnosis, these data were then gathered for research purposes from clinical charts. The
research project was approved by the Institutional Review Board of Università del Piemonte
Orientale.
Statistical analyses were performed using STATA 11 (Stata Corp., College Station, TX, 2011).
Initial descriptive statistics included the χ2 test to evaluate the differences in proportions
between groups (SMI-SUD vs SMI patients in the two periods). Then, a multivariate analysis
was performed using a logistic regression to assess the potential predictors of substance abuse.
The covariates included in the final model were selected using a stepwise forward selection
process, with a univariate p<0.25 as the main criterion [84]. Results are expressed as odds
ratio (OR) with 95% confidence interval (CI). A two-tailed p<0.05 was considered significant
for all analyses.
3. Results
Patients first admitted to our psychiatric ward and matching the inclusion criteria described
above were 227 in 2003–2004 and 257 in 2013–2014, respectively. The percentage of SMI-SUD
patients was 25.1% in 2003–2004 and 32.7% in 2013–2014.
We divided patients in the following age categories: <18, 19–40, 41–60, and ≥61 years. In 2003–
2004, SMI and SMI-SUD patients were 1.8% and 3.5% for <18 years, 42.9% and 56.1% for 19–
40 years, 31.2% and 36.8% for 41–60 years, and 24.1% and 3.5% for ≥61 years, respectively. In
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2013–2014, SMI and SMI-SUD patients were 2.9% and 7.1% for <18 years, 31.8% and 54.8%
for 19–40 years, 38.7% and 33.3% for 41–60 years, and 26.6% and 4.8% for ≥61 years, respec‐
tively. Differences between SMI-SUD and SMI patients in age distribution were statistically
significant in both 2-year periods, and patients in the SMI-SUD group were more frequently
in the age category 19–40 years; moreover, in 2013–2014, this difference was found also in the
age category <18 years.
Table 1 reports data about sociodemographic features in the 2003–2004 and 2013–2014 groups,
further subdivided according to the presence or absence of comorbid SUD. The main statisti‐
cally significant differences between SMI and SMI-SUD patients included gender, occupa‐
tional status, and educational level. SMI-SUD patients compared to SMI patients were more
frequently males (70.2% vs 39.4% in 2003–2004 and 70.2% vs 36.6% in 2013–2014) and
unemployed (33.3% vs 15.0% in 2003–2004 and 41.3% vs 22.5% in 2013–2014) in both 2-year
periods. Furthermore, in 2013–2014, a higher percentage of students (10.0% vs 6.5%) and lower
educational level (junior high school; 63.0% vs 37.3%) were found in SMI-SUD patients
compared to SMI.
2003–2004 (n = 227) 2013–2014 (n = 257)
SMI, % (n) SMI-SUD, % (n) p* SMI, % (n) SMI-SUD, % (n) p*
Gender ≤0.05 ≤0.05
Male 39.4 (67) 70.2 (40) 36.6 (63) 70.2 (59)
Female 60.6 (103) 29.8 (17) 63.4 (109) 29.8 (25)
Nationality 0.209 0.334
Italian 94.1 (160) 98.3 (56) 86.7 (150) 82.1 (69)
Foreign 5.9 (10) 1.8 (1) 13.3 (23) 17.9 (15)
Educational level 0.179 ≤0.05
Primary school 28.8 (49) 28.1 (16) 16.9 (28) 13.6 (11)
Junior high school 38.2 (65) 50.9 (29) 37.3 (62) 63.0 (51)
High school 24.7 (42) 19.3 (11) 37.9 (63) 18.5 (15)
University degree 8.2 (14) 1.8 (1) 7.8 (13) 4.9 (4)
Occupational status ≤0.05 ≤0.05
Employed 38.1 (61) 48.1 (26) 31.4 (53) 33.7 (27)
Unemployed 15.0 (24) 33.3 (18) 22.5 (38) 41.3 (33)
Student 0.0 (0) 0.0 (0) 6.5 (11) 10.0 (8)
Disabled/retired 25.6 (41) 7.4 (4) 29.6 (50) 10.0 (8)
Other 21.3 (34) 11.1 (6) 10. 1(17) 5.0 (4)
Table 1. Sociodemographic features of patients in 2003–2004 and 2013–2014. A comparison of the subgroups of
patients, subdivided according to the presence or absence of comorbid SUD.
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Table 2 describes the living accommodation and family features of patients in 2003–2004
and 2013–2014 and the comparison of the subgroups of patients, subdivided according to the
presence or absence of comorbid SUD. The main statistically significant differences between
SMI and SMI-SUD patients included living accommodation and marital status in both 2-year
periods and having kids in 2013–2014. SMI-SUD patients compared to SMI patients lived more
frequently with their family of origin (33.9% vs 19.2% in 2003–2004 and 33.8% vs 21.2% in 2013–
2014) rather than with a family of their own, and they were more frequently single (48.2% vs
41.3% in 2003–2004 and 60.2% vs 33.5% in 2013–2014) or divorced in 2003–2004 (28.6% vs 12%).
Moreover, in 2013–2014, SMI-SUD patients more frequently had no kids compared to SMI
patients.
2003–2004 (n = 227) 2013–2014 (n = 257)
SMI, % (n) SMI-SUD, % (n) p* SMI, % (n) SMI-SUD, % (n) p*
Accommodation ≤0.05 ≤0.05
Alone 25.8 (43) 23.2 (13) 18.6 (30) 27.3 (21)
With parents 19.2 (32) 33.9 (19) 21.1 (34) 33.8 (26)
Own family 49.1 (82) 28.6 (16) 49.1 (79) 29.9 (19)
Therapeutic community 3.0 (5) 3.6 (2) 7.5 (12) 6.5 (5)
Other 3.0 (5) 10.7 (6) 3.7 (6) 2.6 (2)
Marital status ≤0.05 ≤0.05
Married 38.3 (64) 21.4 (12) 44.1 (75) 22.9 (19)
Single 41.3 (69) 48.2 (27) 33.5 (57) 60.2 (50)
Widowed 8.4 (14) 1.8 (1) 6.5 (11) 3.6 (3)
Divorced 12.0 (20) 28.6 (16) 15.9 (27) 13.2 (11)
Siblings 0.412 0.112
No 22.9 (39) 31.6 (18) 20.0 (31) 29.9 (23)
1 33.5 (57) 31.6 (18) 38.1 (59) 28.2 (22)
≥2 43.5 (74) 36.8 (21) 41.9 (65) 56.4 (44)
Children 0.277 ≤0.05
No 47.1 (80) 50.9 (29) 35.6 (58) 63.3 (50)
1–2 40.0 (68) 43.9 (25) 57.7 (4) 32.9 (26)
≥3 12.9 (22) 5.3 (3) 6.8 (11) 3.8 (3)
Table 2. Living accommodation and family features of patients in 2003–2004 and 2013–2014. A comparison of the
subgroups of patients subdivided according to the presence or absence of comorbid SUD.
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Family problems were reported as significantly more common by SMI-SUD patients in the
years 2003–2004 than in SMI patients (21.1% vs 8.2 %, p=0.009), although no statistically
significant difference was found between the two groups in the years 2013–2014 (47.9% vs
44.0%, p=0.588). Similarly, patients’ parents were divorced in a significantly higher percentage
of SMI-SUD patients than in SMI patients in the years 2003–2004 (7.0% vs 1.8%, p=0.047),
although no significant difference was found in the two groups for this variable in the years
2013–2014 (84.2% vs 76.9%, p=0.604).
2003–2004 (n = 227) 2013–2014 (n = 257)
SMI, % (n) SMI-SUD, % (n) p* SMI, % (n) SMI-SUD, % (n) p*
Diagnosis ≤0.05 ≤0.05
Affective disorders 24.1 (41) 10.5 (6) 17.9 (31) 4.8 (4)
Schizophrenia/psychosis 25.3 (43) 7.0 (4) 22.5 (39) 26.2 (22)
Personality disorders 23.5 (40) 52.6 (30) 19.1 (33) 23.8 (20)
Anxiety disorders 7.6 (13) 0.0 (0) 30.1 (52) 22.6 (19)
Other 19.4 (33) 29.8 (17) 10.4 (18) 22.6 (19)
Self-injury behaviors 32.9 (56) 26.3 (15) 0.350 35.3 (60) 30.0 (24) 0.408
Acts of harm 4.7 (8) 12.3 (7) ≤0.05 11.8 (20) 26.3 (21) ≤0.05
Imprisonment 1.8 (3) 8.8 (5) ≤0.05 2.9 (5) 7.4 (6) 0.104
Table 3. Clinical features of patients in 2003–2004 and 2013–2014. Comparison of the subgroups of patients subdivided
according to the presence or absence of comorbid SUD.
Table 3 reports the clinical and legal features of patients in 2003–2004 and 2013–2014, and the
results of the comparison of the subgroups of patients, subdivided according to the presence
or absence of comorbid SUD. The main statistically significant differences between SMI and
SMI-SUD patients included diagnosis and acts of harm in both 2-year periods and imprison‐
ment in 2003–2004. In 2003–2004, SMI-SUD patients compared to SMI patients were more
frequently diagnosed with a personality disorder (52.6% vs 23.5%). In 2013–2014, the same
difference was found, albeit less striking (23.8% vs 19.1%), together with a higher percentage
of schizophrenia and psychosis in SMI-SUD patients compared to SMI patients (26.2% vs
22.5%). Acts of harm were more common in SMI-SUD patients than in SMI ones in both
periods (12.3% vs 4.7% in 2003–2004 and 26.3% vs 11.8% in 2013–2014), whereas imprison‐
ment was significantly more common in SMI-SUD patients only in 2003–2004 (8.8% vs 1.8%).
The following variables were included in the multivariate analysis: gender, nationality,
educational level, occupation, marital status, living accommodation, family problems, acts of
harm, imprisonment, age at admission, and diagnosis. The statistically significant results of
the multivariate analysis performed to investigate the possible predictors of comorbidity with
SUD are described in Table 4.
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In both 2-year periods, female gender and age >61 years were associated with comorbidity
with SUD with an OR <1 (adjusted OR 0.24, 95% CI 0.09–0.64, p=0.004 vs adjusted OR 0.15,
95% CI 0.06–0.39, p<0.001; adjusted OR 0.92, 95% CI 0.01–0.81, p=0.031 vs adjusted OR 0.03,
95% CI 0.01–0.31, p=0.003).
In 2003–2004, having a university degree was associated with a decreased risk of comorbid
SUD (adjusted OR 0.04, 95% CI 0.01–0.64, p=0.023), whereas having a diagnosis of personali‐
ty disorder was associated with an increased risk of SMI-SUD comorbidity (adjusted OR 3.51,
95% CI 1.05–11.77, p=0.042).
In 2013–2014, living in therapeutic rehabilitation center (compared to living alone) was
associated with a decreased risk of SMI-SUD comorbidity (adjusted OR 0.02, 95% CI 0.01–0.41,
p=0.011).
2003–2004 2013–2014
OR (95% CI) p OR (95% CI) p
Gender 0.24 (0.09–0.64) ≤0.05 0.15 (0.06–0.39) ≤0.05
Education level
Primary school Ref. – Ref. –
Junior high school 0.46 (0.12–1.69) 0.239 0.63 (0.14–2.81) 0.546
High school 0.40 (0.10–1.64) 0.205 0.19 (0.04–1.03) 0.054
University degree 0.04 (0.01–0.64) ≤0.05 0.65 (0.08–5.02) 0.675
Accommodation status
Alone Ref. – Ref. –
With parents 3.63 (0.92–14.27) 0.065 0.87 (0.23–3.26) 0.837
Own family 1.11 (0.17–7.14) 0.916 0.49 (0.12–1.98) 0.318
Therapeutic community 0.45 (0.04–5.84) 0.544 0.02 (0.01–0.41) ≤0.05
Other 5.40 (0.56–52.40) 0.146 0.63 (0.07–5.91) 0.691
Age at admission
19–40 years old Ref. – Ref. –
<18 years old 1.39 (0.15–12.88) 0.771 0.60 (0.07–5.16) 0.644
41–60 years old 0.90 (0.30–2.74) 0.851 0.66 (0.23–1.87) 0.437
≥61 years old 0.92 (0.01–0.81) ≤0.05 0.03 (0.01–0.31) ≤0.05
Disease
Affective disorders Ref. – Ref. –
Psychosis/schizophrenia 0.29 (0.06–1.38) 0.120 0.77 (0.16–3.68) 0.739
Personality disorders 3.51 (1.05–11.77) ≤0.05 2.21 (0.44–11.01) 0.334
Anxiety disorders – – 0.96 (0.22–4.18) 0.961
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2003–2004 2013–2014
OR (95% CI) p OR (95% CI) p
Other 3.94 (0.99–15.69) 0.052 3.11 (0.56–17.11) 0.192
Table 4. Multivariate analysis for the assessment of potential predictors of comorbid SUD in psychiatric patients in
2003–2004 and 2013–2014.
As far as substance used is concerned, the assessment of the SMI-SUD sample in 2003–2004
and 2013–2014 highlighted a decrease of alcohol (78.9% of SMI-SUD patients in 2003–2004 vs
64.6% of SMI-SUD patients in 2013–2014) and heroin consumption (19.2% of SMI-SUD patients
in 2003–2004 vs 14.6% of SMI-SUD patients in 2013–2014). Polyabuse did not seem to change
after 10 years (42.1% vs 42.6%). On the contrary, we found an increase of the use of medica‐
tion, cannabinoids, cocaine, and other drugs (0.05% vs 17.0%, 33.3% vs 57.3%, 28.0% vs 36.5%,
and 0.05% vs 17.0%, respectively).
4. Discussion
The percentage of first admissions for SMI-SUD increased from the first to the second 2-year
period considered (2003–2004 vs 2013–2014), being 25.1% and 32.7%, respectively. Accord‐
ing to the existing literature, DD is a growing phenomenon. Studies performed in similar
settings report a percentage of DD patients ranging from 24% to 51% [85,86]. In Italy, data from
mental health departments and from addiction services describe a prevalence of psychiatric
disorders with comorbid SUD ranging from 4% to 42%, respectively [87–91].
4.1. Sociodemographic and family features
Statistically significant differences were found in both periods between SMI and SMI-SUD
patients as far as gender, age at admission, occupational status, marital status, and living
accommodation are concerned. With more detail, SMI-SUD patients in both 2-year periods
were more likely to be male, younger, unemployed, living with parents (or alone, for the 2013–
2014 period) rather than with a family of their own, and single (or divorced, in 2003–2004). All
these results are in line with similar reports from most other studies in this field. Regarding
marital status and living accommodation, DD patients seem to experience relational prob‐
lems in their families and have difficulties either creating or maintaining lasting relation‐
ships. Besides, comorbidity of psychiatric disorders and SUD may impact on relationships in
and of itself. In a previous study [65], we found that this impact was particularly meaningful
in female patients. Some differences between SMI and SMI-SUD patients were not shared
between the two 2-year periods. For instance, in the 2-year period 2013–2014, SMI-SUD
patients were more likely than SMI ones to have a junior high school degree rather than a high
school one or a university degree and to have no kids [92]. On the contrary, family problems
and parents’ divorce were reported as significantly more common by SMI-SUD patients in the
years 2003–2004 than in SMI patients. We may suppose an evolving pattern of substance
seeking through the years; it may be that the motivation leading to addiction is shifting in most
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cases from relief of psychological and emotional distress to active search for pleasure and
entactogenic effects. This hypothesis is consistent with the widespread changes in the choice
of the main substance of abuse.
Overall, consistent with the literature [91,93], what emerges from these data is that SMI-SUD
patients are more likely to have a poorer sociorelational functioning and achievement, albeit
our results do not allow to discriminate which came first, whether comorbidity or a poorer
performance, which are likely to be strictly intertwined.
4.2. Clinical features
In both 2-year periods examined, psychiatric diagnosis was significantly different between
SMI-SUD and SMI patients. This difference is striking in 2003–2004 patients: SMI-SUD patients
are more frequently affected by personality disorders and “other” diagnoses (including
disturbance of conduct, mental retardation, eating disorders, acute stress reaction, and
adaptation reaction), whereas, in 2013–2014, there is still a difference as far as personality
disorders is concerned, albeit less striking, together with differences in “other” diagnoses and
schizophrenia, which is more frequent in SMI-SUD than in SMI patients. These results are
partially consistent with the existing literature [37,94–97] especially because of the under-
representation of mood disorders in the SMI-SUD group of patients. On the contrary, this
change in diagnosis is interesting, as it may suggest a different pattern of substance use after
10 years. It seems that schizophrenic and psychotic patients are more likely, in recent years, to
use substances, but it is not clear whether this change suggests a trend towards more self-
medication seeking on behalf of these patients or rather a greater potential of substances to
induce long-lasting psychotic symptoms. It should be considered that the type of substances
used have changed a lot over a decade; cannabinoid, ecstasy, and new drugs are studied for
their potential of inducing psychosis, and in clinical settings, it is quite common to observe
long-lasting, medication-resistant psychotic symptoms in young patients who have taken one
of the several new synthetic drugs. Besides, these are difficult or impossible to identify and
detect with standard laboratory methods.
As far as acts of harm are concerned, these were significantly more common in SMI-SUD
patients than in SMI ones, in both 2-year periods, and overall, the percentage of acts of harm
was higher in 2013–2014. Several studies have focused on the relation between substance abuse
and aggressive behaviors; the use of substances may result in poor insight, neurocognitive
impairments, hallucinations, impulsivity, as well as other emotional or physiological prob‐
lems that may underlie aggressiveness. Moreover, some studies report that SMI-SUD patients
are more likely to have a criminal history and legal problems than SMI ones [36]. Violent
behaviors and substance abuse may be entangled because of the close relationship between
drug distribution and the criminal system; moreover, the constant need of money to get the
drug may lead patients to aggressive acts to obtain it [98]. Despite the almost 2-fold increase
in the percentage of acts of harm from 2003–2004 to 2013–2014, only in 2003–2004 was the
frequency of imprisonment significantly different in SMI-SUD and SMI patients, being higher
in the first.
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As far as substance used is concerned, our findings are consistent with the literature and with
clinical observations, especially regarding the increased use of cannabinoids, cocaine, and
“other” drugs on the one hand and the decreased consumption of heroin on the other.
Surprisingly, we found polyabuse to be relatively stable even after 10 years.
4.3. Multivariate analysis
In both 2-year periods, female gender and being ≥61 years old appear to be associated with a
decreased risk of SMI-SUD comorbidity. Both results are consistent with the existing litera‐
ture and could be expected according to clinical experience [66,85–87,91].
In the 2-year period 2003–2004, having a university degree was associated with a decreased
risk of comorbid SMI-SUD, whereas having a diagnosis of personality disorder was associat‐
ed with an increased risk of comorbid SMI-SUD, but 10 years later we found educational level
and diagnosis having no impact on comorbidity. As already described above, this may suggest
possible changes in the pattern of SUD as far as problematic family issues are concerned;
notwithstanding the fact that, in 2013–2014, educational level and diagnosis no longer
represented risk factors, it would have been interesting to assess whether individuals with
different cultural levels as assessed by schooling of with different diagnosis share the same
pathways towards SUD and similar choices regarding type of substance and use. As far as
educational level is concerned, in a recent study, we found that, although having a universi‐
ty degree was associated with a decreased risk of DD for males, it was associated with an
increased risk of DD in females [65]. We hypothesized a different pattern of social function‐
ing and performance in male and female SMI-SUD patients [44] and that males and females
may access substances via different pathways and choose different types of substances as
well [99–102], with a variable impact on their lives.
As far as diagnosis is concerned, the same study mentioned above, which assessed the
period 2003–2012, found affective and “other” disorders associated with an increased risk of
comorbid SUD, compared to personality disorders, which according to Baigent [94] would be
more likely than Axis I disorders to be associated with chronic SUD. On the contrary, reports
from the literature show mixed results about this issue, and recent studies suggest that the
frequency of comorbid SUD is similar in schizophrenic psychoses and in personality disor‐
ders [37] and that primary mood and/or anxiety disorders are at high risk for comorbid SUD
as well [96,97].
Last, in the 2-year period 2013–2014, we found that living in therapeutic rehabilitation centers
was associated with a decreased risk (compared to living alone) of comorbidity with SUD. This
result is encouraging and may support the effectiveness of such therapeutic settings in
protecting patients from exposition and/or relapse into SUD.
5. Limitations
Some limitations should be underscored. The retrospective design and data gathering through
clinical charts entail some limitations. Some information could not be retrieved, for example,
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detailed descriptions of type of self-harm or aggressive behavior. Psychiatric diagnoses were
grouped into broad categories (affective disorders, schizophrenia and other psychosis,
personality disorders, anxiety disorders, and others), and we did not discriminate between
bipolar and unipolar affective disorders. We did not include data about laboratory tests
objectively detecting drugs; nonetheless, it has been suggested that a urine drug screening can
only identify a small additional rate (5%) of substance users [52]. Although it would have been
interesting to assess details about reason for “acute” inpatient psychiatric admission, in this
study, we focused specifically on a “snapshot” of comorbidity in a psychiatric ward over a 10-
year period. Last, we cannot exclude that our results might have been influenced by broader
systemic differences in the treatment of the DD population across time. Anyway, in our
country, in the study period, there have neither been relevant changes in treatment options
available for DD patients, not in the legal policies about drugs.
6. Conclusions
This study adds to the scant literature about this issue in our country, and the large sample
size is a strength of this research. Both SMI and SUD are predictors of underachievement and
failure in educational and occupational settings, difficulty facing family responsibilities,
violent and abusing behaviors, poverty, legal problems, and scarce compliance to treatment
[103]. Acute settings may be particularly appropriate for the development of targeted
interventions [104], and the treatment of patients with comorbid psychiatric disorders and
SUD should begin early during hospitalization [105].
Changes in the pathways leading to drug abuse and in the patterns of addiction should not be
overlooked.
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